Vera Therapeutics downgraded by Wolfe Research
$VERA
Biotechnology: Pharmaceutical Preparations
Health Care
Wolfe Research downgraded Vera Therapeutics from Outperform to Peer Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2025 | $48.00 | Buy | BofA Securities |
| 8/4/2025 | Outperform → Peer Perform | Wolfe Research | |
| 5/5/2025 | $75.00 | Buy | H.C. Wainwright |
| 2/4/2025 | $49.00 | Outperform | Wolfe Research |
| 1/28/2025 | $58.00 | Buy | Goldman |
| 11/21/2024 | $70.00 | Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 1/25/2024 | $26.00 | Outperform | Oppenheimer |
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
SCHEDULE 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
3 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
BofA Securities initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $48.00
Wolfe Research downgraded Vera Therapeutics from Outperform to Peer Perform
H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut
BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: 8th Annual Evercore Healthcare ConferenceFormat: Fireside Chat and 1x1sWebcast: https://wsw.com/webcast/evercore52/vera/2362844Date: Tuesday, December 2, 2025 Time: 8:45am ET Location: Coral Gables, FL Citi 2025 Global Healthcare ConferenceFormat: Fireside Chat and 1x1
BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Thursday, November 13, 2025 Time: 1:30pm ETWebcast: https://wsw.com/webcast/cowen185/vera/2021228 A replay of the event will be available for 90 days and can be access
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, and comparable to placebo Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la
BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics' Board of Directors. "We are thrilled to welcome Jim to our Board of Directors at this pivotal point in Vera Therapeutics' history as we prepare to launch a potential first-in-class dual BAFF/APRIL inhibitor to transform the treatment of IgA nephropathy and other aut
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)